A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Conditions:   ER+ Breast Cancer;   HER2-negative Breast Cancer Interventions:   Drug: Palbociclib 125Mg Tab;   Drug: Fulvestrant injection;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Exemestane;   Drug: Anastrozole Sponsors:   Royal Marsden NHS Foundation Trust;   Pfizer;   AstraZeneca;   Institute of Cancer Research, United Kingdom;   UNICANCER;   Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials